GenVec to Participate in Focus Session at the BIO CEO & Investor
Conference
GAITHERSBURG, Md., Feb. 18 /PRNewswire-FirstCall/ --
GenVec, Inc.
(NASDAQ:GNVC) today announced that the Company's President and CEO, Paul H.
Fischer, Ph.D., will participate as a panelist in a focus session at the BIO
CEO & Investor Conference on Wednesday, February 23, 2005 at 4:00 PM Eastern
Standard Time. The panel, which will discuss progress in the field of gene
therapy, will be followed by a brief breakout session. The focus session will
be webcast live and will be available for 24 hours following the session. To
access the webcast, please visit GenVec's website at http://www.genvec.com/ and
click on the Webcasts option tab.
GenVec is a biopharmaceutical company developing treatments for cancer, heart
disease, vision loss, and vaccines for infectious diseases. GenVec's product
candidates in clinical development include TNFerade(TM) for locally advanced
pancreatic cancer, BIOBYPASS(R) for severe coronary artery disease, and AdPEDF
for wet age-related macular degeneration. Additional information on GenVec is
available at http://www.genvec.com/ and in GenVec's various filings with the
Securities and Exchange Commission.
Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters, including
expectations regarding future studies and programs, are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act.
GenVec cautions that these forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Factors that may
cause actual results to differ materially from the statements herein include
risks relating to the early stage of product candidate development; GenVec's
ability to secure and maintain relationships with collaborators; uncertainties
with, and unexpected results and related analyses relating to, clinical trials
of GenVec's product candidates; the growth of revenues attributable to GenVec's
vaccine program; the timing and content of future U.S. Food and Drug
Administration regulatory actions with respect to GenVec, its product
candidates, or its collaborators; dependence on the efforts of third parties;
dependence on intellectual property; risks that GenVec may lack the financial
resources and access to capital to fund its operations; and risks relating to
the commercialization, if any, of GenVec's product candidates (such as
marketing, regulatory, patent, product liability, supply, competition and other
risks). Further information on the factors and risks that could affect
GenVec's business, financial conditions and results of operations is contained
in GenVec's filings with the U.S. Securities and Exchange Commission (SEC),
which are available at http://www.sec.gov/. These forward-looking statements
speak only as of the date of this press release, and GenVec assumes no duty to
update forward-looking statements.
DATASOURCE: GenVec, Inc.
CONTACT: Rena Cohen, Corporate Communications, of GenVec, Inc.,
+1-240-632-5501, or
Web site: http://www.genvec.com/